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Template-based stabilization of a-peptide helices with short accessory non-peptide helical
foldamers fused either at the N- or C-terminus or at both ends of the peptide segment has
been investigated by NMR spectroscopy in polar solvents and by X-ray diffraction. In this
work, we focused on aliphatic N,N0-linked oligoureas that form predictable and well-
deﬁned helical structures akin to a-helices. Our results indicate that urea oligomers
have the ability to enforce a peptide segment to adopt a well-deﬁned a-helical structure
and may suggest a general approach to stabilize short helical peptide epitopes for the
development of modulators of proteineprotein interactions.
© 2015 Academie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).r e s u m e
Nous avons etudie la capacite de foldameres accessoires non peptidiques fusionnes a
l’une ou l’autre, ou aux deux extremites d’une sequence peptidique, a servir de matrice
de nucleation d’une structure helicoïdale dans la partie peptidique. Dans ce but, nous
avons choisi de travailler avec des oligomeres d’urees N, N’-liees connus pour former des
structures helicoïdales bien deﬁnies et presentant une certaine ressemblance avec
l’helice a. Les resultats de cette etude par RMN et par diffraction des rayons X indiquent
que de courts segments oligourees ont la capacite d’induire une conformation en helice
a dans la section peptidique adjacente, ce qui permet de suggerer une methode pourMR 5248, Institut Europeen de Chimie et Biologie (IECB), 2 rue Robert Escarpit, 33607 Pessac, France.
G. Guichard).
ed by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://
L. Mauran et al. / C. R. Chimie 19 (2016) 123e131124stabiliser des epitopes peptidiques adoptant une conformation en helice au contact de
leur cible en vue de developper de nouveaux modulateurs des interactions proteine-
proteine.
© 2015 Academie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Regular secondary structures such as a-helices are
essential components of protein architectures and are
frequently found at proteineprotein interfaces [1]. The
coiled-coil motif which consists of two ormore amphiphilic
a-helical segments interacting together by interdigitation
of their hydrophobic side chains is also common among
protein tertiary structures and protein oligomerization
domains [2]. The knowledge of these proteineprotein in-
teractions (PPIs) at atomic resolution has provided the basis
for diverse applications of helically folded synthetic pep-
tides including, for example, the modulation of therapeu-
tically relevant PPIs [3,4] or the construction of bioinspired
self-assembled (one-dimensional or three-dimensional)
nanostructures [5,6]. However, in the absence of addi-
tional stabilizing effects (packing, favorable electrostatic
interactions, and N- and C-capping motifs) [7,8], short
peptide helices are only weakly populated in water thus
limiting the development of their therapeutic applications.
Today, a number of synthetic strategies are available to
further increase the stability of short-chain a-helices,
among which are the insertion of conformationally con-
strained amino acids (e.g., Ca-tetrasubstituted amino acids
such as a-amino isobutyric acid, Aib [9,10], and b-amino
acids [11]), side chain crosslinking [12,13], and helix
nucleating templates [14e16]. The latter approach is aimed
at pre-organizing the ﬁrst amide bonds through the use of a
rigid template generally placed at the N-terminus of the
peptide chain (e.g., Kemp tricyclic templates [17,18]) or a
hydrogen bond surrogate (HBS) in which the N-terminal
intramolecular i,iþ4 hydrogen bond is substituted with a
covalent linkage (e.g., Arora HBS helices [19,20]). More
recently, chiral templates have also been used to control
helix screw sense preference in a-peptides made of heli-
cogenic achiral Aib residues [21,22].
Surprisingly and despite potential interest, the use of a
helical foldamer (synthetic folded oligomer) [23e25] as a
template to nucleate/stabilize peptide helices has hardly
been investigated; (ab þ a) peptides disclosed by the
Gellman group represent to our knowledge the only case in
the literature of a foldamer/a-peptide chimera mimicking
an a-helix [26,27]. Most of the published studies are rather
related to hybrid foldamer sequences whereby a-amino
acid residues alternate with non-natural monomer units
[28e30]. We [31] and others [32] have recently started to
explore the concept of foldamer/a-peptide chimeras (or
block co-foldamers as termed by Clayden [32]) with
aliphatic oligoureas, a class of foldamers that adopt well-
deﬁned and stable helical structures akin to a-helices
(similar helicity, polarity and pitch but a more complex
three centred H-bond network and a larger diameter,
Fig. 1a) [33e38]. In a previous study, we have shown thatoligourea/peptide chimeras form well-deﬁned helical
structures in polar organic solvents with the propagation of
a continuous intramolecular H-bond network spanning the
entire sequence and connecting two geometrically distinct
helices (a-helix and oligourea 2.5-helix) [31]. Furthermore,
our results in solution also suggest that short triurea se-
quences have the ability to induce a-helicity when fused to
either the N- or C-terminus of a peptide segment.
To gain additional insight into the a-helix stabilization
properties of oligoureas, we have now investigated the
folding properties of peptide-oligourea-peptide and
oligourea-peptide-oligourea chimeras 1 and 2 containing
14 and 13 residues, respectively (Fig. 1b). Sequence 1which
contains a 6-mer oligourea motif ﬂanked by two tetra-
peptide units is aimed at testing the ability of a central
oligourea chain to induce helix formation concurrently in
the two peptide regions. Oligomer 2 was designed to
evaluate whether two triurea units fused at the N- and C-
termini of a peptide segment can work synergistically to
promote a-helicity. In both sequences, the peptide segment
is composed of alternating Ala and Leu residues, both
known for their helix forming tendency [39,40].
2. Results and discussion
Both oligomers 1 and 2 have been synthesized by a
solid-phasemethodology starting from a Sieber amide resin
[41] as shown in Scheme 1. Oligourea segments were
assembled by coupling succinimidyl (2-azidoethyl)carba-
mate derivatives 3 (with side chains of Val, Ala and Leu)
using microwave assistance followed by the reduction of
azido groups under Staudinger conditions as previously
described [42]. The peptide segments were built using
standard Fmoc chemistry. Only the last Ala residue in 1 and
the last urea unit in 2 were coupled as N-Boc protected
monomers. Cleavage from the resin was performed by
treatment with 1% TFA in CH2Cl2 thus allowing the N-ter-
minal Boc protecting group to be preserved. The two olig-
omers were puriﬁed to homogeneity by C18 RP-HPLC and
their identity was conﬁrmed by mass spectrometry and
NMR in CD3OH. The frequencies of all 1H, 13C and 15N atoms
were assigned by using homonuclear COSY, TOCSY and
NOESYexperiments and heteronuclear experiments (Tables
1 and 2). The assignment of spin systems and conforma-
tional investigation of the two chimeras were facilitated by
the dispersion and by the distinct ranges of chemical shifts
of amide and urea NH resonances, amide NHs appearing
systematically downﬁeld to urea NHs (in the range of
7.2e9.1 ppm in 1 and 7.2e8.9 ppm in 2).
Oligomer 1 consists of a 6 mer oligourea chain pro-
longed at both ends by a Ala-Leu-Ala-Leu tetrapeptide
sequence. Inspection of the oligourea NH/CH ﬁngerprint
region in the 1H NMR spectra reveals features typical of
Fig. 1. a) Comparison of peptide a-helical and oligourea 2.5-helical backbones (green and light grey, respectively); b) principle of a-helix nucleation by oligourea
segments in triblock oligomers and primary sequences of triblock chimeras 1 and 2 studied in this work. The standard three letter code is used for a-amino acid
residues (green), and a superscript “u” is added for the corresponding urea units (light grey).
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coupling constants between NH and CH(R) protons
(3J> 9 Hz) and a high degree of anisochronicity (Dd) of main
chain methylene protons (0.81 < Dd < 1.35 ppm) [43e45].
Furthermore, the presence of unambiguous non-sequential
nuclear Overhauser enhancements (NOEs) along the oli-
gourea backbone such as bN(i,iþ 2) and bN0(i,iþ 2) are fully
consistent with helix formation in the oligourea segment
[43]. The observation in the two peptide regions of an un-
interrupted NN(i, i þ 1) pattern of NOEs indicates that the
peptide backbone also adopts a helical conformation
(Fig. 2). This is supported by the presence of non-sequential
medium range (i,iþ 2), (i,iþ 3) NOEs in the peptide regions
and at the junction between the peptide and oligourea
segments (e.g., bN(9,12), bN(9,13), and a2N(9,13) connec-
tivities, Fig. 2b). However, because medium range NOEs
between peptide and oligourea protons are non canonical,
it is difﬁcult to discriminate between a possible a-helical
conformation and a 310-helical conformation for the short
peptide segments. The values of the vicinal 3J (NH, aCH)
coupling constants in the peptide segments are slightly
above those reported for stable a- and 310 helical structuresScheme 1. (a) Fmoc-Xaa-OH or Boc-Ala-OH (4 equiv), HBTU (4 equiv), HOBt (4 equ
DMF, MW (50 W, 50 C), 8 min; (c) 3aec or 4 (3 equiv), DIPEA (6 equiv), DMF, MW (
30 min; (e) 1% TFA in CH2Cl2.(<6 Hz) [46] thus suggesting helix fraying. Nevertheless,
this NMR study tends to suggest that a helical structure
develops without a break between the three segments,
thus conﬁrming the compatibility of both helix geometries
and related H-bonding networks.
The 1H NMR spectrum of triblock chimera 2 shares a
number of features with that of chimera 1, including large
>9.5 Hz 3J(NH, bCH) and anisochronicity of main chain
methylene protons along the oligourea backbone, which
altogether are indicative of a helical conformation [43].
Remarkably, ﬁve out of the seven vicinal 3J (NH, aCH)
coupling constants in the peptide segment are below 6 Hz
(3e5.8 Hz), supporting the view that the peptide region is
also helical in solution. The non-sequential medium range
bN(i,iþ 2) and bN0(i,i þ 2) in the two oligourea segments as
well as NN(i, i þ 1), aN(i,i þ 3), aN(i,i þ 2) and aN(i,i þ 4)
NOEs along the peptide chain observed in the NOESY
spectrum of 2 are also consistent with the formation of a
seamless helical conformation with no apparent interrup-
tion at the two peptide/oligourea junctions (Fig. 3).
Circular dichroism also proved useful to characterize the
conformational preference of chimera 2. The spectrumiv), DIPEA (8 equiv), DMF, MW (50 W, 50 C), 10 min; (b) 20% piperidine in
50 W, 50 C), 10 min; (d) PMe3, 1,4-dioxane/H2O (7:3, v/v), MW (50 W, 50 C),
Table 1
1H, 13C and 15N chemical shifts for compound 1 in CD3OH (700 MHz) at 4 mM.
Residue HN HN0 Ha Hb Hg Hd Hd1 Hd2 H 31 H 32
N N0 Ca Cb Cg Cd Cd1 Cd2 C 31 C 32
Ala (1) 7.35 3.91 1.37
125.2 55.9 19.7
Leu (2) 8.52 4.07 1.59/1.70 1.76 0.92 0.99
116.9 58.2 42.6 28.1 24.3 25.0
Ala (3) 7.86 4.29 1.49
118.8 55.0 19.5
Leu (4) 7.49 4.19 1.65/1.78 1.77 0.92 0.98
117.5 58.0 43.5 28.1 24.3 25.0
Val u (5) 7.28 5.78 2.80/3.61 3.97 1.73 0.91 0.94
119.4 nd 44.7 57.4 34.1 23.1 22.1
Ala u (6) 5.65 6.06 2.50/3.57 3.87 1.05
126.2 nd 50.0 48.9 20.6
Leu u (7) 5.98 6.48 2.52/3.65 3.94 1.21/1.27 1.75 0.93 0.93
123.9 109.7 49.0 51.4 44.9 28.1 24.3 24.3
Val u (8) 6.40 6.66 2.42/3.77 3.52 1.62 0.90 0.94
120.9 110.8 46.7 59.0 34.3 20.8 22.1
Ala u (9) 6.06 6.48 2.33/3.57 4.13 1.03
127.5 109.7 50.4 48.8 20.6
Leu u (10) 5.92 6.65 2.31/3.57 3.98 1.10/1.22 1.75 0.85 0.92
121.7 110.8 47.4 50.0 44.3 28.1 24.1 26.2
Ala (11) 7.33 3.91 1.37
124.3 55.9 19.7
Leu (12) 9.06 4.25 1.55/2.05 1.88 0.91 0.96
115.0 57.2 41.5 28.3 23.1 25.7
Ala (13) 8.5 4.3 1.5
120.6 53.9 19.5
Leu (14) 7.57 4.27 1.65/1.79 1.75 0.88 0.94
117.6 55.4 43.5 28.1 16.6 25.7
13C and 15N chemical shifts are in italics.
1H chemical shifts are not italicized.
Table 2
1H, 13C and 15N chemical shifts for compound 2 in CD3OH (700 MHz) at 4 mM.
Residue HN HN0 Ha Hb Hg Hd Hd1 Hd2 H 31 H 32
N N0 Ca Cb Cg Cd Cd1 Cd2 C 31 C 32
Val u (1) 6.61 6.00 3.57/2.47 3.38 1.56 0.84 0.88
123.8 107.4 46.2 60.1 34.2 25.7 22.3
Ala u (2) 5.84 5.70 3.52/2.24 4.04 0.98
125.7 nd 50.5 48.8 20.0
Leu u (3) 5.90 6.63 3.55/2.26 3.91 1.09/1.09 1.66 0.80 0.83
121.8 110.4 49.7 50.2 28.1 24.4 25.7
Ala (4) 7.19 3.84 1.31
124.0 57.2 20.2
Leu (5) 8.90 4.18 1.88/1.61 1.72 0.84 0.91
116.0 57.9 42.0 28.3 24.0 25.2
Ala (6) 7.99 4.03 1.48
121.6 56.1 18.8
Leu (7) 7.77 3.97 1.67/1.58 1.65 0.81 0.87
118.4 58.8 42.5 28.1 21.0 22.3
Ala (8) 8.01 3.92 1.45
120.7 55.9 18.4
Leu (9) 7.66 4.08 1.80/1.49 1.79 0.81 0.86
117.5 58.2 43.2 27.8 21.6 24.0
Ala (10) 8.05 4.03 1.43
121.4 56.1 20.0
Val u (11) 7.47 5.81 3.50/2.75 3.85 1.62 0.81 0.81
118.9 nd 44.4 55.7 34.4 21.0 21.0
Ala u (12) 5.4 5.8 3.42/2.44 3.99 0.96
nd nd 50.1 47.8 20.8
Leu u (13) 6.00 6.40 3.50/2.68 3.85 1.13/1.23 1.63 0.85 0.85
123.8 nd 47.7 51.5 46.0 28.1 25.70 25.70
13C and 15N chemical shifts are in italics.
1H chemical shifts are not italicized.
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Fig. 2. (a) Overview of sequential and medium-range 1He1H NOEs observed
in the peptide and oligourea domains of 1 and spin-spin-coupling constants
3J(NH, aCH) measured in the peptide chain. The thickness of the bars is
proportional to the intensity of the observed NOEs. *indicates signal overlaps
precluding unambiguous NOE assignment; (b) some key medium range NOE
connectivities (light orange) between oligourea and peptide segments in 1.
Fig. 3. (a) Overview of sequential and medium-range 1He1H NOEs observed
in the peptide and oligourea domains of 2 and spin-spin-coupling constants
3J(NH, aCH) measured in the peptide chain. The thickness of the bars is
proportional to the intensity of the observed NOEs. *indicates signal overlaps
precluding unambiguous NOE assignment; (b) some key medium range NOE
connectivities (light orange) between oligourea and peptide segments in 2.
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was found to combine the hallmarks of both helically fol-
ded oligourea and a-peptide backbones. The spectrum is
largely dominated by the contribution of the urea chro-
mophore with a strong positive maximum at ca 203 nm
characteristic of the oligourea 2.5-helical structure. A
negativemaximum at ca 222 nm is also observed that is not
present in the spectra of the cognate homooligourea 5 and
chimera 1 (see Supporting information). This signal can
thus be tentatively ascribed to the peptide a-helical
conformation and the corresponding molar ellipticity at
222 nm is likely to reﬂect the degree of a-helicity inchimera 2. However, due to the presence of two distinct
chromophores and helix types in the main chain, the
spectra of chimeras should be analyzed with caution and
our interpretation at that stage remains largely tentative.
Nevertheless, the ellipticity value at 222 nm for 2 in MeOH
surpasses that measured for the parent heptapeptide 6 in
bothMeOH or TFE, supporting a stabilizing effect of the two
oligourea domains in 2.
Additional insight into the conformation of triblock
chimeras was obtained by high resolution crystallographic
structural studies. Single crystals of chimera 2 suitable for
X-ray diffraction were grown from a DMF solution and the
Table 3
X-ray crystallographic parameters for chimera 2.
CCDC number CCDC 1041244
Formula C69H132N20O15
Crystal System Orthorhombic
Space Group P212121
Z 4
Unit cell parameters
a, Å 46.115(4)
b, Å 11.5920(9)
c, Å 16.7751(13)
a,  90
b,  90
g,  90
Temperature, K 130(2)
Volume, Å3 8967.4(12)
FW, g mol1 1157.59
r, g cm3 1.098
l, Å 1.54187
Mu, E 0.638
q min/q max 2.803/60.948
Radiation source Rotating anode
Reﬂections measured 21785
Reﬂections unique ( [Fo > 2sFo)]) 11484
Parameters/restraints 938/58
GOF 1.091
R1 (I > 2s(I)) 0.1067
wR2 (all data) 0.2547
Fig. 4. X-ray crystal structure representations (side view and top view) of
chimera 2 with details of the H-bonding network at the two peptide/oli-
gourea junctions. Intramolecular H-bonds between peptide and oligourea
segments are shown in slate blue. C atoms in the oligourea and peptide
segments are shown in light grey and light green, respectively.
L. Mauran et al. / C. R. Chimie 19 (2016) 123e131128structure was solved in the P212121 space group (Table 3).
The structure shows a continuous and regular helix that
spans the entire sequence with no apparent distortion and
with all intramolecular complementary H-bonding sites
being satisﬁed. (Fig. 4). Closer inspection of the structure
revealed useful details about the propagation of the H-
bonding network and the way the oligourea and peptide
helices communicate. The geometry of the helical peptide
segment in the crystal structure of 2 is particularly notable.
The F andJ dihedral angles of amino acid in the structure
of 2 (mean F and J values for the seven residues : 69,
41) match almost perfectly those of a canonical a-helix
(63, 42) [47]. The two terminal oligourea segments
adopt a canonical 2.5-helical conformation [37,44]. A series
of speciﬁc, non canonical bifurcated H-bonds are observed
at the junction between the oligourea and peptide parts at
both ends of the peptide sequence. In particular, urea car-
bonyls of Alau2 and Leuu3 are both engaged in H-bonds
with iþ3 and iþ4 amide protons (i.e., NHs of L5, A6 and L7).
In a similar manner, amide carbonyls of Leu7 and Ala8 form
a continuous network of four H-bonds with NHs of Leuu11
and Alau12. In contrast, amide carbonyls of Leu9 and Ala10
form two centered i,iþ3 H-bonds with N0H and NH of
Alau12 and Leuu13, closing 15- and 14-membered pseu-
docycles, respectively. Overall, the medium range NOEs
between main chain NH and CH protons of the junction
region (see for example aN(2,5), bN(2,5), aN(7,11), and
aN(8,11) connectivities in Fig. 3b) are in good agreement
with the short distances measured in the crystal structure,
thus further supporting the conclusion that the molecule is
largely helical in solution.
3. Conclusion
Herein, we have studied helix propagation and a-helix
nucleation in peptide-oligourea-peptide and oligourea-
peptide-oligourea triblock oligomers. Our results ob-
tained in a polar organic solvent (methanol) and in the
crystal state conﬁrm the ability of oligourea segments as
short as triureas to serve as nucleation templates when
located either at the N- or C-terminus [31,32] or at both
ends of a short peptide sequence. The crystal structure of
the 13-mer chimera 2 reveals the formation of a regular
helix that spans the entire sequence. In this structure, the
peptide part in the middle of the sequence adopts a ca-
nonical a-helical conformation which is locked at both
ends by two short 2.5 oligourea helices. This observation
suggests a synchronized effect of both accessory foldamers
in nucleating the a-helical structure and a possible strat-
egy to stabilize a-helical peptides targeting protein sur-
faces. The oligourea backbone which is strongly biased
towards helix formation provides a pre-organized cap for
the initial four peptide NHs and ﬁnal four carbonyl groups.
It is noteworthy that most synthetic a-helical templates
[8,14,15] reported in the literature are designed to engage
H-bonds in the initial turn of the helix but relatively few
molecules have been shown to effectively cap the carbonyl
groups in the ﬁnal turns of the helix [48]. Similar a-helix
capping effects also take place in proteins [49]. To some
extent, the complementary H-bonded network observed
in 2 can be compared to that of native capping motifs
L. Mauran et al. / C. R. Chimie 19 (2016) 123e131 129found at the N- and C-termini of a-helices in proteins such
as the N-terminal capping box [50,51], or the C-terminal
Schellman motif [52,53]. Overall these ﬁndings and the
high resolution structural data reported here may suggest
a possible strategy based on oligourea foldamers to sta-
bilize helical peptide epitopes for protein ligand design.
Our progress in this direction will be reported in due
course.
4. Experimental
4.1. General
Abbreviations : DIPEA (diisopropylethylamine), DMF
(dimethylformamide), HBTU (N,N,N0,N0-Tetramethyl-O-
(1H-benzotriazol-1-yl)uronium hexaﬂuorophosphate),
HOBT (1-Hydroxybenzotriazole), and TFA (triﬂuoroacetic
acid). Analytical RP-HPLC analyses were performed on a
Dionex U3000SD using a MachereyeNagel Nucleodur
column (4.6  100 mm, 3 mm) at a ﬂow rate of 1 ml/min
with UV detection at 200 nm. The mobile phase
was composed of 0.1% (v/v) TFA-H2O (Solvent A) and 0.1%
(v/v) TFA-MeOH (Solvent B). Semi-preparative puriﬁca-
tion of chimeras was performed on a Dionex U3000SD
using a MachereyeNagel Nucleodur column
(10  250 mm, 5 mm) at a ﬂow rate of 4 ml/min with UV
detection at 200 nm. ESI-MS analyses were carried out on
a ThermoElectron LCQ Advantage spectrometer equipped
with an ion trap mass analyzer and coupled with a
ThermoElectron Surveyor HPLC system. Succinimidyl (2-
azido-1-X-ethyl)carbamate monomers with side chains
of Ala (3a), Val (3b) and Leu (3c) and succinimidyl {(2S)-
2-{[(tert-butoxy)carbonyl]amino}}-3-methylbutyl} carba-
mate 4 were prepared using previously described pro-
cedures [42,54].
4.2. Synthesis
4.2.1. General procedure for oligomer synthesis on a solid
support (GP1)
Solid-phase synthesis of chimeras 1 and 2 was con-
ducted with microwave irradiation using the Discover Bio®
System from CEM. All steps were performed under mi-
crowave irradiation at atmospheric pressure. The tem-
perature was maintained by modulation of power and
controlled with a ﬁber optic sensor. The starting Sieber
amide resin [41] (z100 mg, loading 0.62 mmol/g) was
swelled in DMF (2 mL) for 30 min prior to the synthesis.
The Fmoc-group was then removed with 20% piperidine in
DMF (2 mL), under microwave irradiation (50 W, 50 C,
8 min). Amide bond and urea bond formation were
monitored by the Kaiser test [55] and the chloranil test,
respectively.
4.2.2. General procedure for coupling a-amino acids (GP2)
N-Fmoc-a-amino acids or Boc-Ala-OH (used as N-ter-
minal residue in the synthesis of 1) (0.248 mmol, 4 equiv),
HBTU (0.094 g, 0.248 mmol), HOBt (0.038 g, 0.248 mmol)
and DIPEA (0.086 mL, 0.496 mmol) were dissolved in DMF
and after 5 min the mixture was added into a reactionvessel (CEM). The vessel was then placed inside the mi-
crowave reactor and irradiated for 10 min (50 W, 50 C).
The resin was then ﬁltered and washed with DMF
(4  2 mL).
4.2.3. General procedure for the Fmoc deprotection (GP3)
The N-Fmoc protecting group was removed with 20%
piperidine in DMF (2 mL), under microwave irradiation
(50 W, 50 C, 8 min).
4.2.4. General procedure for coupling succinimidyl carbamates
(GP4)
Activated monomer 3 or 4 (used as the N-terminal
residue in the synthesis of 2) (0.186 mmol, 3 equiv) was
dissolved in DMF (2 mL) and was added to the reaction
vessel, followed by DIPEA (0.065 mL, 0.372 mmol, 6 equiv).
The reaction was performed under microwave irradiation
for 20 min (50 W, 50 C). The resin was then ﬁltered and
washed with DMF (4  2 mL).
4.2.5. General procedure for the reduction of the azide moiety
on a solid support (GP5)
The reduction of the azido group was performed in a
mixture of 1,4-dioxane/H2O (7:3 v/v). The resin was ﬁrst
washed with this mixture of solvents and the Staudinger
reaction was then performed under microwave conditions
(50 W, 50 C, 30 min) by treating a suspension of the resin
in 1,4-dioxane/H2O (2 mL) with a 1 M PMe3 solution in THF
(0.62 mL, 10 equiv). After completion, the resin was ﬁltered
off and washed with 1,4-dioxane/H2O (7:3 v/v, 1  2 mL)
and DMF (4  2 mL).
4.2.6. General procedure for the cleavage from the resin (GP6)
After completion of the last coupling (Boc protected
monomer), the resin was transferred into a syringe with a
frit, washed with DMF (5  2 mL), CH2Cl2 (5  2 mL), and
Et2O (5  2 mL) and dried in a desiccator. Before the
cleavage step, the resin was swelled in CH2Cl2 (2 mL) for
2 h. The cleavage was performed under mild acidic con-
ditions, with 1% TFA in CH2Cl2 (1 mL) for 2 min. This step
was repeated 10 times. After every 2 min, the resin was
ﬁltered directly into the solution of 10% pyridine in
MeOH (2 mL) to neutralize the TFA. The mixture was
concentrated to about 5% of the volume and cooled in an
ice/water bath. H2O was added to precipitate the product
as a creamy solid. The precipitation was ﬁltered and
washed few times with H2O, and dried in the desiccator.
Boc-Ala-Leu-Ala-Leu-Valu-Alau-Leuu-Valu-Alau-Leuu-
Ala-Leu-Ala-Leu-NH2 (1). Chimera 1 was synthesized ac-
cording to the general procedures GP1eGP6 starting from
Sieber amide resin (100 mg, 0.062 mmol). The ﬁnal product
1 was puriﬁed by semi preparative C18 RP-HPLC to give
8 mg (5% overall yield); RP-HPLC (H2O (0.1% TFA), MeOH
(0.1% TFA); gradient 50e100%, 5 min; 100%, 5 min)
tR ¼ 7.79 min; 1H NMR (CD3OH): Table 1; 13C NMR
(CD3OH): Table 1; ESI-MS (M ¼ 1594.1): m/z 798.0
[Mþ2H]2þ, 1594.9 [MþH]þ, 1617.1 [MþNa]þ.
Boc-Valu-Alau-Leuu-Ala-Leu-Ala-Leu-Ala-Leu-Ala-Valu-
Alau-Leuu-NH2 (2). Chimera 2 was synthesized according
the general procedures GP1eGP6 starting from Sieber
L. Mauran et al. / C. R. Chimie 19 (2016) 123e131130amide resin (162 mg, 0.10 mmol). The ﬁnal product 2 was
puriﬁed by semi preparative C18 RP-HPLC to give 28 mg
(18% overall yield); RP-HPLC (H2O (0.1% TFA), MeOH (0.1%
TFA); gradient 50e100%, 5 min; 100%, 5 min)
tR ¼ 7.55 min; 1H NMR (CD3OH): Table 2; 13C NMR
(CD3OH): Table 2; ESI-MS (M ¼ 1481.02): m/z 763.5
[Mþ2H]2þ, 1504.1 [MþNa]þ.4.3. NMR conformational analysis
Experiments have been performed on a Bruker Avance
III 700 MHz spectrometer equipped with a 5 mm diameter
BBI Gradient probe. Water suppressionwas achievedwith a
watergate sequence. Experiments were processed with the
Bruker software (Bruker BioSpin, Courtaboeuf, France) and
analyzed with the Sparky program (T. D. Goddard and D. G.
Kneller, University of California, San Francisco). Chimeras 1
and 2 were dissolved in 100% CD3OH to a ﬁnal concentra-
tion of 4 mM. For each peptide, a complete series of 2D
homonuclear and heteronuclear spectra was acquired at
293 K. A number of scans of 16, 8, and 32 were used,
respectively, for COSY-DQF, TOCSY and ROESY experiments.
The mixing times were set up to 60 ms for TOCSY and
300 ms for ROESY experiments. The 2D homonuclear
spectra were acquired with 215 increments in F1 dimen-
sion and 2048 points in F2 dimension. The heteronuclear
1H15N and 1H13C spectra were acquired, respectively, with
38 and 128 increments in F1 dimension and with a number
of scans of 1024 and 128. The 1H, 15N and 13C spectral width
was set up, respectively, to 14, 22 and 120 ppm.4.4. X-ray diffraction studies
Crystallographic data were collected at the IECB X-ray
facility on a high ﬂuxmicrofocus Rigaku FRX rotating anode
at the copper ka wavelength equipped with a Dectris
Pilatus 200 K hybrid detector and Varimax HF optics at
130 K. The crystal was mounted on a cryo-loop after quick
soaking on ParatonedN oil from Hampton research and
ﬂash-frozen. The data were processed using the Crystal-
Clear suite version 2.1b25. The crystal structure was solved
using SHELXD and reﬁned with SHELXL 2013 version [56].
Full-matrix least-squares reﬁnement was performed on F2
for all unique reﬂections, minimizing w(Fo2-Fc2)2, with
anisotropic displacement parameters for non-hydrogen
atoms. Hydrogen atoms were positioned at idealized po-
sitions and reﬁned with a riding model, with Uiso con-
strained to the 1.2 Ueq value of the parent atom (1.5 Ueq
when CH3). The positions and isotropic displacement pa-
rameters of the remaining hydrogen atoms were reﬁned
freely. SIMU and DELU commands were used to restrain
some side chains as rigid groups and restrain their
displacement parameters. The BYPASS/SQUEEZE [57] pro-
cedure was used to take into account the electron density
in the potential solvent area.
CCDC-1041244 contains the supplementary crystallo-
graphic data for this paper. These data can be obtained free
of charge from The Cambridge Crystallographic Data Centre
via www.ccdc.cam.ac.uk/data_request.cif.Acknowledgements
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